CANOPY_1170x120_9-21-20

Aimovig

Novartis and Amgen announce FDA approval of Aimovig

Novartis and Amgen announce FDA approval of Aimovig

Basel, SWITZERLAND – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to

FDA approves new preventive treatment for migraines

FDA approves new preventive treatment for migraines

WASHINGTON — The U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that